SRP330452 PRJNA750738 GSE181117 miRNA regulation of T cell exhaustion in cutaneous T cell lymphoma [CTCL_antimir] Cobomarsen (MRG-106), an oligonucleotide inhibitor of miR-155, has been evaluated in a clinical phase 1/2 trial for CTCL. We used lesional skin samples from 6 CTCL patients to identify the critical pathways affected by miR-155 inhibition in CTCL. Overall design: 6 CTCL patients (baseline and after 4 weeks of treatment with cobomarsen to identify the critical pathways affected by miR-155 inhibition in CTCL. GSE181117 pubmed 34831008 parent_bioproject PRJNA750770